Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL5206400 | 0.93 | SLC16A3 (0.32) | SLC16A3SLC16A1 | |
| Pyridine SCHEMBL5241809 | 0.74 | NOTUM (0.32) | DGAT1SLC16A3SLC16A1 | |
| Pyridine SCHEMBL6069596 | 0.73 | — | — | |
| SCHEMBL1417532 | 0.72 | NPC1 (0.39) | DGAT1KMT2A | |
| SCHEMBL31336489 | 0.72 | NPC1 (0.39) | DGAT1KMT2A | |
| SCHEMBL31662301 | 0.69 | KMT2A (0.37) | DGAT1KMT2A | |
| SCHEMBL30286434 | 0.69 | KMT2A (0.36) | DGAT1KMT2A | |
| SCHEMBL21988942 | 0.69 | KMT2A (0.36) | DGAT1KMT2A | |
| SCHEMBL22732169 | 0.69 | STING1 (0.38) | DGAT1 | |
| SCHEMBL12670980 | 0.68 | PLA2G4A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585743-B1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2006-07-20 | — | — | US | disclosed |
| US-7053107-B2 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1585743-A1 | 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004056806-A1 | 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES | PFIZER INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192735-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | DGAT1 3266/4885SLC16A3 4838/4885SLC16A1 4859/4885 |
| US-20060160858-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, CNKSR1 | DGAT1 3266/4885SLC16A3 4838/4885SLC16A1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.